BIMZELX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BIMZELX (BIMZELX).
BIMZELX (bimekizumab) is a humanized monoclonal IgG1 antibody that selectively neutralizes interleukin-17A (IL-17A) and interleukin-17F (IL-17F), inhibiting their binding to the IL-17 receptor and subsequent pro-inflammatory signaling.
| Metabolism | Bimekizumab is likely degraded into small peptides and amino acids via general protein catabolism. It is not metabolized by CYP450 enzymes. |
| Excretion | Bimekizumab is a monoclonal antibody that is degraded into small peptides and amino acids via general protein catabolism; no renal or biliary excretion of intact antibody. Fecal excretion of degraded fragments is minor (<1%). |
| Half-life | Terminal elimination half-life is approximately 26 days (range 22–29 days) across approved doses; supports every 4-week subcutaneous dosing. |
| Protein binding | Approximately 99% bound to target (IL-17A and IL-17F) in serum; albumin binding is negligible. |
| Volume of Distribution | Volume of distribution at steady state is approximately 7.0 L (0.1 L/kg assuming 70 kg), indicating limited extravascular distribution, consistent with a monoclonal antibody primarily in plasma and interstitial fluid. |
| Bioavailability | Subcutaneous: Approximately 80% (range 60–100%) compared to intravenous administration. |
| Onset of Action | Subcutaneous: Clinical improvement (e.g., reduction in Psoriasis Area and Severity Index) can be observed as early as week 4, with initial onset within 2–4 weeks. |
| Duration of Action | Sustained clinical response for 48 weeks (clinical trial duration); pharmacodynamic effects on IL-17A/F persist for several half-lives after drug clearance. Dosing interval is every 4 weeks. |
Subcutaneous injection: 160 mg (two 80 mg injections) at week 0, week 2, week 4, then every 4 weeks.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (eGFR <30 mL/min/1.73 m2). |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C). |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No specific dose adjustment recommended; pharmacokinetics similar to younger adults in clinical studies with patients up to 75 years. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BIMZELX (BIMZELX).
| Breastfeeding | It is unknown whether bimekizumab is excreted in human milk or absorbed systemically after ingestion. Monoclonal antibodies are generally present in breast milk at very low concentrations with limited oral bioavailability due to protein digestion in the infant's gastrointestinal tract. The M/P ratio has not been determined. Due to the potential for adverse reactions in the breastfed infant, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. |
| Teratogenic Risk | Bimekizumab is a humanized monoclonal IgG1 antibody that inhibits IL-17A and IL-17F. As a large protein, it is transported across the placenta via FcRn-mediated transfer, with fetal levels increasing during the second and third trimesters. Available data are insufficient to determine a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Animal studies showed no evidence of teratogenicity or fetal harm in monkeys at doses up to 100 mg/kg (approximately 30 times the human exposure at the recommended dose). However, monoclonal antibodies are known to cross the placenta, and the theoretical risk of fetal immune suppression exists. Therefore, bimekizumab should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. |
■ FDA Black Box Warning
None.
| Common Effects | Itching Burning sensation Stinging sensation Pain |
| Serious Effects |
["Known hypersensitivity to bimekizumab or any excipient","Active tuberculosis or other severe infections"]
| Precautions | ["Increased risk of infections, including serious infections; avoid use during active infection","Hypersensitivity reactions including urticaria and angioedema","Exacerbation of inflammatory bowel disease (Crohn's disease or ulcerative colitis)","Potential for increased suicidality or depression; monitor for neuropsychiatric symptoms","Avoid live vaccines during treatment","Tuberculosis screening prior to initiation"] |
| Food/Dietary | There are no known food interactions with BIMZELX. Take with or without food. |
Loading safety data…
| Fetal Monitoring | No specific clinical monitoring is required for maternal-fetal safety beyond routine prenatal care. However, as bimekizumab may increase the risk of infections, including tuberculosis, assess for active tuberculosis prior to initiating therapy and monitor for signs and symptoms of infection during pregnancy. If a live vaccine is required, the infant's vaccination status should be considered after maternal biologic exposure. |
| Fertility Effects | No clinical studies have been conducted to evaluate the effects of bimekizumab on human fertility. In animal studies, no adverse effects on male or female fertility were observed in monkeys at doses up to 100 mg/kg (approximately 30 times the human exposure at the recommended dose) over 6 months. However, as IL-17A and IL-17F are involved in reproductive function, a theoretical risk for impaired fertility cannot be excluded. |
| Clinical Pearls | BIMZELX (bimekizumab) is a humanized monoclonal IgG1 antibody that selectively inhibits both IL-17A and IL-17F. It is administered subcutaneously with a loading dose at weeks 0, 2, 4, then every 8 weeks. Monitor for exacerbations of inflammatory bowel disease (Crohn's or ulcerative colitis) as IL-17 inhibition can rarely trigger or worsen these conditions. Do not administer live vaccines during treatment. Consider tuberculosis screening prior to initiation. |
| Patient Advice | You may be at increased risk of infections, including upper respiratory tract infections and oral candidiasis. Report any signs of infection to your healthcare provider promptly. · If you have a history of inflammatory bowel disease (Crohn's disease or ulcerative colitis), tell your doctor before starting treatment, as this medicine can worsen it. · Do not receive live vaccines while on BIMZELX. Discuss any required vaccinations with your doctor before starting therapy. · This medication is given as an injection under the skin. You or your caregiver can be trained to administer it at home. Rotate injection sites and do not inject into tender, bruised, or scarred skin. · Store BIMZELX in the refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light. Keep in original carton until use. |